NHS Dudley Health Economy Medicines Formulary
Home > 10 Musculoskeletal and joint diseases > 10.1 Drugs used in rheumatic diseases and gout > 10.1.4 Gout and cytotoxic-induced hyperuricaemia > Gout (tophaceous, severe debilitating, chronic) - pegloticase - NICE TAG TA291

Gout (tophaceous, severe debilitating, chronic) - pegloticase - NICE TAG TA291

1.1 Pegloticase is not recommended within its marketing authorisation, that is, for treating severe debilitating chronic tophaceous gout in adults who may also have erosive joint involvement and in whom xanthine oxidase inhibitors at the maximum medically appropriate dose have failed to normalise serum uric acid, or for whom these medicines are contraindicated.

1.2 People currently receiving pegloticase that is not recommended according to 1.1 should be able to continue treatment until they and their clinician consider it appropriate to stop.

https://www.nice.org.uk/guidance/tA291

Site by Devopa
© Copyright 2019 NHS. All rights reserved.